Candel Therapeutics Inc (CADL) is -10.25% away from 50-day simple Moving Average despite all headwinds

On Friday, Candel Therapeutics Inc (NASDAQ: CADL) opened higher 4.70% from the last session, before settling in for the closing price of $5.11. Price fluctuations for CADL have ranged from $3.79 to $14.60 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. Company’s average yearly earnings per share was noted 40.03% at the time writing. With a float of $36.44 million, this company’s outstanding shares have now reached $49.25 million.

In an organization with 38 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Candel Therapeutics Inc (CADL) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Candel Therapeutics Inc is 26.97%, while institutional ownership is 38.00%. The most recent insider transaction that took place on Mar 18 ’25, was worth 396,995. In this transaction Chief Medical Officer of this company sold 45,316 shares at a rate of $8.76, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Scientific Officer sold 32,146 for $8.76, making the entire transaction worth $281,673. This insider now owns 96,527 shares in total.

Candel Therapeutics Inc (CADL) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 40.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.77% during the next five years compared to -43.86% drop over the previous five years of trading.

Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators

Check out the current performance indicators for Candel Therapeutics Inc (CADL). In the past quarter, the stock posted a quick ratio of 4.64.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.29 in one year’s time.

Technical Analysis of Candel Therapeutics Inc (CADL)

Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was inferior than the volume of 1.14 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 74.17%. Additionally, its Average True Range was 0.42.

During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 11.66%, which indicates a significant decrease from 80.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.72% in the past 14 days, which was lower than the 101.14% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $5.96, while its 200-day Moving Average is $6.49. However, in the short run, Candel Therapeutics Inc’s stock first resistance to watch stands at $5.54. Second resistance stands at $5.72. The third major resistance level sits at $5.95. If the price goes on to break the first support level at $5.13, it is likely to go to the next support level at $4.90. The third support level lies at $4.72 if the price breaches the second support level.

Candel Therapeutics Inc (NASDAQ: CADL) Key Stats

There are currently 50,103K shares outstanding in the company with a market cap of 268.05 million. Presently, the company’s annual sales total 0 K according to its annual income of -55,180 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -14,070 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.